A Prospective, Single-Center, Single-Arm, Exploratory Study of 177Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
In brief
177Lu-LNC1010 PRRT produces 44% tumor shrinkage in advanced neuroendocrine cancers
In a single-center trial of 22 patients with progressive metastatic NETs, four cycles of 177Lu-LNC1010 achieved partial responses in 44% and disease control in 94%, with a median progression-free survival of 15 months. Grade 3-4 blood toxicities occurred in 27% but no severe kidney or liver injury, suggesting a promising efficacy-safety balance that warrants further study.
- Journal
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine (Q1)
- Published
- 3 September 2026
- Study design
- Non-randomized / quasi-experimental trial
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Wei Guo, Chunlei Fan, Yuhang Chen, Shan Yu, Guanming Yue, Tianzhi Zhao, et al.
- PMID
- 42692826
- DOI
- 10.2967/jnumed.126.272607
Why clinicians should know about it
- Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (paper of the day, 4 September 2026): PRRT with 177Lu‑LNC1010 shows safety and efficacy
Abstract
Rapid radiopharmaceutical clearance limits the efficacy of peptide receptor radionuclide therapy (PRRT) for the treatment of advanced neuroendocrine tumors (NETs). In this prospective, single-center, single-arm, investigator-initiated trial, we evaluated the safety and efficacy of 177Lu-LNC1010-an optimized, long-acting somatostatin analog-in patients with progressive metastatic NETs. Methods: Twenty-two patients with unresectable, metastatic NETs and disease progression despite treatment with somatostatin analogs or tyrosine kinase inhibitors were enrolled in the study. Participants received up to 4 cycles of PRRT with 177Lu-LNC1010 (3.3 GBq/cycle) at 8-wk intervals. Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. The treatment response was evaluated using RECIST 1.1. Kaplan-Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Results: The patients (13 men, 9 women; median age, 50.5 y) received 69 PRRT cycles in total. Treatment-related grade 3 or 4 hematologic toxicities were observed in 6 patients (27%). No grade 3 or higher nephrotoxicity or hepatotoxicity was recorded. The median absorbed tumor dose was 2.12 (interquartile range: 1.68-2.96) Gy/GBq. Response after PRRT was assessed in 18 patients. A partial response was achieved in 8 patients (44.0%), stable disease in 9 (50.0%), and progressive disease in 1 (5.6%). The objective response rate was 44.4%, and the disease control rate was 94.4%. After a median follow-up of 21.0 mo, the median PFS was 15.0 mo, and the median OS was not reached. Conclusion: PRRT with 3.3 GBq/cycle of 177Lu-LNC1010 was well-tolerated and exhibited an acceptable safety profile. The objective response rate and disease control rate were high and positively correlated with improved PFS and OS. Appropriate patient selection and earlier intervention may further optimize the therapeutic benefit.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.